Signaling receptors for TGF-β family members

Cold Spring Harbor Perspectives in Biology

Volumn 8, Issue 8, 2016, Pages

  Heldin, Carl Henrik ^a   Moustakas, Aristidis ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; MICRORNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

CELL NUCLEUS; CYTOPLASM; ENDOCYTOSIS; HUMAN; METABOLISM; PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; SUMOYLATION; UPREGULATION;

CELL NUCLEUS; CYTOPLASM; ENDOCYTOSIS; HUMANS; MEMBRANE PROTEINS; MICRORNAS; PHOSPHORYLATION; PROTEIN TRANSPORT; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84982840895     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a022053     Document Type: Article

References (287)

1. Abdalla SA, Cymerman U, Rushlow D, Chen N, Stoeber GP, Lemire EG, Letarte M. 2005. Novel mutations and polymorphisms in genes causing hereditary hemorrhagic telangiectasia. Hum Mutat 25: 320-321.
2. Abdollah S, Macías-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL. 1997. TbRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 272: 27678-27685.
3. Akhurst RJ, Hata A. 2012. Targeting the TGFb signalling pathway in disease. Nat Rev Drug Discov 11: 790-811.
4. Al-Salihi MA, Herhaus L, Macartney T, Sapkota GP. 2012. USP11 augments TGF b signalling by deubiquitylating ALK5. Open Biol 2: 120063.
5. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E, Charlton R, Parums DV, Jowett T, Marchuk DA, et al. 2000. Endoglin, an ancillary TGFb receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 217: 42-53.
6. Aspalter IM, Gordon E, Dubrac A, Ragab A, Narloch J, Vizan P, Geudens I, Collins RT, Franco CA, Abrahams CL, et al. 2015. Alk1 and Alk5 inhibition by Nrp1 controls vascular sprouting downstream of Notch. Nat Commun 6: 7264.
7. Atfi A, Dumont E, Colland F, Bonnier D, L’Helgoualc’h A, Prunier C, Ferrand N, Clement B, Wewer UM, Theret N. 2007. The disintegrin and metalloproteinase ADAM12 contributes to TGF-β signaling through interaction with the type II receptor. J Cell Biol 178: 201-208.
8. Babitt JL, Huang FW, Wrighting DM, Xia Y, Sidis Y, Samad TA, Campagna JA, Chung RT, Schneyer AL, Woolf CJ, et al. 2006. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38: 531-539.
9. Bagarova J, Vonner AJ, Armstrong KA, Borgermann J, Lai CSC, Deng DY, Beppu H, Alfano I, Filippakopoulos P, Morrell NW, et al. 2013. Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol Cell Biol 33: 2413-2424.
10. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE, Pollock BH, Mundy GR, Sun LZ. 2006. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-b type I receptor kinase inhibitor. Cancer Res 66: 6714-6721.
11. Bandyopadhyay B, Han A, Dai J, Fan J, Li Y, Chen M, Woodley DT, Li W. 2011. TbRI/Alk5-independent TbRII signaling to ERK1/2 in human skin cells according to distinct levels of TbRII expression. J Cell Sci 124: 19-24.
12. Barbara NP, Wrana JL, Letarte M. 1999. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-b superfamily. J Biol Chem 274: 584-594.
13. Barrios-Rodiles M, Brown KR, Ozdamar B, Bose R, Liu Z, Donovan RS, Shinjo F, Liu Y, Dembowy J, Taylor IW, et al. 2005. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307: 1621-1625.
14. Batut J, Schmierer B, Cao J, Raftery LA, Hill CS, Howell M. 2008. Two highly related regulatory subunits of PP2A exert opposite effects on TGF-β/activin/nodal signalling. Development 135: 2927-2937.
15. Bian Y, Caldes T, Wijnen J, Franken P, Vasen H, Kaklamani V, Nafa K, Peterlongo P, Ellis N, Baron JA, et al. 2005. TGFBR1 6A may contribute to hereditary colorectal cancer. J Clin Oncol 23: 3074-3078.
16. Biswas S, Trobridge P, Romero-Gallo J, Billheimer D, Myeroffs LL, Willson JKV, Markowitz SD, Grady WM. 2008. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor b resistant cells. Genes Chromos Cancer 47: 95-106.
17. Bizet AA, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J, Finnson KW, Buschmann MD, Philip A. 2011. The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptors. Biochem Biophys Acta 1813: 742-753.
18. Bizet AA, Tran-Khanh N, Saksena A, Liu K, Buschmann MD, Philip A. 2012. CD109-mediated degradation of TGF-β receptors and inhibition of TGF-β responses involve regulation of SMAD7 and Smurf2 localization and function. J Cell Biochem 113: 238-246.
19. Bourguignon LY, Singleton PA, Zhu H, Zhou B. 2002. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor b receptor I in metastatic breast tumor cells. J Biol Chem 277: 39703-39712.
20. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. 2009. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 104: 1184-1191.
21. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, Morrison A, Lewis P, Bouffet E, Bartels U, et al. 2014. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46: 451-456.
22. Budi EH, Muthusamy BP, Derynck R. 2015. The insulin response integrates increased TGF-β signaling through Akt-induced enhancement of cell surface delivery of TGF-β receptors. Sci Signal 8: e80630.
23. Cao Y, Szabolcs A, Dutta SK, Yaqoob U, Jagavelu K, Wang L, Leof EB, Urrutia RA, Shah VH, Mukhopadhyay D. 2010. Neuropilin-1 mediates divergent R-Smad signaling and the myofibroblast phenotype. J Biol Chem 285: 31840-31848.
24. Chaikuad A, Alfano I, Kerr G, Sanvitale CE, Boergermann JH, Triffitt JT, von Delft F, Knapp S, Knaus P, Bullock AN. 2012. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem 287: 36990-36998.
25. Champion A, Kreis M, Mockaitis K, Picaud A, Henry Y. 2004. Arabidopsis kinome: After the casting. Funct Integr Genomics 4: 163-187.
26. Chan MC, Nguyen PH, Davis BN, Ohoka N, Hayashi H, Du K, Lagna G, Hata A. 2007. A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor. Mol Cell Biol 27: 5776-5789.
27. Chan MC, Hilyard AC, Wu C, Davis BN, Hill NS, Lal A, Lieberman J, Lagna G, Hata A. 2010. Molecular basis for antagonism between PDGF and the TGFb family of signalling pathways by control of miR-24 expression. EMBO J 29: 559-573.
28. Chang CYY, Chen Y, Lai MT, Chang HW, Cheng J, Chan C, Chen CM, Lee SC, Lin YJ, Wan L, et al. 2013. BMPR1B up-regulation via a miRNA binding site variation defines endometriosis susceptibility and CA125 levels. PLoS ONE 8: e80630.
29. Chen RH, Derynck R. 1994. Homomeric interactions between type II transforming growth factor-b receptors. J Biol Chem 269: 22868-22874.
30. Chen YG, Liu F, Massagué J. 1997. Mechanism of TGFb receptor inhibition by FKBP12. EMBO J 16: 3866-3876.
31. Chen TP, Carter D, Garrigue-Antar L, Reiss M. 1998. Transforming growth factor-b type I receptor kinase mutant–associated with metastatic breast cancer. Cancer Res 58: 4805-4810.
32. Chen T, Yan W, Wells RG, Rimm DL, McNiff J, Leffell D, Reiss M. 2001. Novel inactivating mutations of transforming growth factor-b type I receptor gene in head-and-neck cancer metastases. Int J Cancer 93: 653-661.
33. Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang XF, Lefkowitz RJ, Blobe GC. 2003. b-arrestin 2 mediates endocytosis of type III TGF-β receptor and down-regulation of its signaling. Science 301: 1394-397.
34. Chen XW, Wang HT, Liao HJ, Hu W, Gewin L, Mernaugh G, Zhang S, Zhang ZY, Vega-Montoto L, Vanacore RM, et al. 2014. Integrin-mediated type II TGF-β receptor tyrosine dephosphorylation controls SWIAD-dependent profibrotic signaling. J Clin Invest 124: 3295-3310.
35. Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkles L, Goumans MJ, Seehra J, Heldin CH, ten Dijke P, Pietras K. 2010. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 207: 85-100.
36. Daly AC, Randall RA, Hill CS. 2008. Transforming growth factor b-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 28: 6889-6902.
37. Datta PK, Moses HL. 2000. STRAP and Smad7 synergize in the inhibition of transforming growth factor b signaling. Mol Cell Biol 20: 3157-3167.
38. Datta PK, Chytil A, Gorska AE, Moses HL. 1998. Identification of STRAP, a novel WD domain protein in transforming growth factor-b signaling. J Biol Chem 273: 34671-34674.
39. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. 2007. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953-1961.
40. De Boeck M, ten Dijke P. 2012. Key role for ubiquitin protein modification in TGFb signal transduction. Ups J Med Sci 117: 153-165.
41. Derynck R, Miyazono K, ed. 2008. The TGF-β family. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
42. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. 2003. Distinct endocytic pathways regulate TGF-β receptor signalling and turnover. Nat Cell Biol 5: 410-421.
43. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. 2007. The type III TGF-β receptor suppresses breast cancer progression. J Clin Invest 117: 206-217.
44. Durrington HJ, Upton PD, Hoer S, Boname J, Dunmore BJ, Yang J, Crilley TK, Butler LM, Blackbourn DJ, Nash GB, et al. 2010. Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J Biol Chem 285: 37641-37649.
45. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K. 2001. Smurf1 interacts with transforming growth factor-b type I receptor through Smad7 and induces receptor degradation. J Biol Chem 276: 12477-12480.
46. Eddahibi S, Morrell N, d’Ortho MP, Naeije R, Adnot S. 2002. Pathobiology of pulmonary arterial hypertension. Eur Respir J 20: 1559-1572.
47. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, Ishikawa Y, Nomura K, Yokoo H, Shimizu T, et al. 2007. Ki26894, a novel transforming growth factor-b type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98: 127-133.
48. Ehrlich M, Gutman O, Knaus P, Henis YI. 2012. Oligomeric interactions of TGF-β and BMP receptors. FEBS Lett 586: 1885-1896.
49. Eichhorn PJ, Rodon L, Gonzalez-Junca A, Dirac A, Gili M, Martinez-Saez E, Aura C, Barba I, Peg V, Prat A, et al. 2012. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat Med 18: 429-435.
50. Eickelberg O, Centrella M, Reiss M, Kashgarian M, Wells RG,. 2002. Betaglycan inhibits TGF-β signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem 277: 823-829.
51. Elderbroom JL, Huang JJ, Gatza CE, Chen J, How T, Starr M, Nixon AB, Blobe GC. 2014. Ectodomain shedding of TbRIII is required for TbRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion. Mol Biol Cell 25: 2320-2332.
52. Faherty N, Curran SP, O’Donovan H, Martin F, Godson C, Brazil DP, Crean JK. 2012. CCN2/CTGF increases expression of miR-302 microRNAs, which target the TGFβ type II receptor with implications for nephropathic cell phenotypes. J Cell Sci 125: 5621-5629.
53. Felici A, Wurthner JU, Parks WT, Giam LR, Reiss M, Karpova TS, McNally JG, Roberts AB. 2003. TLP, a novel modulator of TGF-β signaling, has opposite effects on Smad2-and Smad3-dependent signaling. EMBO J 22: 4465-4477.
54. Feng XH, Derynck R. 1997. A kinase subdomain of transforming growth factor-b (TGF-β) type I receptor determines the TGF-β intracellular signaling specificity. EMBO J 16: 3912-3923.
55. Feng XH, Derynck R. 2005. Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol 21: 659-693.
56. Feng NH, Xu B, Tao J, Li PC, Cheng G, Min ZC, Mi YY, Wang ML, Tong N, Tang JL, et al. 2012. A miR-125b binding site polymorphism in bone morphogenetic protein membrane receptor type IB gene and prostate cancer risk in China. Mol Biol Rep 39: 369-373.
57. Ferrand N, Atfi A, Prunier C. 2010. The oncoprotein c-ski functions as a direct antagonist of the transforming growth factor-b type I receptor. Cancer Res 70: 8457-8466.
58. Ferrigno O, Lallemand F, Verrecchia F, L’Hoste S, Camonis J, Atfi A, Mauviel A. 2002. Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-β/Smad signaling. Oncogene 21: 4879-4884.
59. Finger EC, Lee NY, You HJ, Blobe GC. 2008. Endocytosis of the type III transforming growth factor-b (TGF-β) receptor through the clathrin-independent/lipid raft path way regulates TGF-β signaling and receptor down-regulation. J Biol Chem 283: 34808-34818.
60. Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S, Bizet AA, Philip A. 2006. Identification of CD109 as part of the TGF-β receptor system in human keratinocytes. FASEB J 20: 1525-1527.
61. Foletta VC, Lim MA, Soosairajah J, Kelly AP, Stanley EG, Shannon M, He W, Das S, Massagué J, Bernard O. 2003. Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. J Cell Biol 162: 1089-1098.
62. Galliher AJ, Schiemann WP. 2006. b3 integrin and Src facilitate transforming growth factor-b mediated induction of epithelial-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 8: R42.
63. Galliher AJ, Schiemann WP. 2007. Src phosphorylates Tyr284 in TGF-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res 67: 3752-3758.
64. Galliher-Beckley AJ, Schiemann WP. 2008. Grb2 binding to Tyr284 in TbR-II is essential for mammary tumor growth and metastasis stimulated by TGF-β. Carcinogenesis 29: 244-251.
65. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, et al. 2006. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-b type I receptor kinase in vivo. Clin Cancer Res 12: 4315-4330.
66. Gilboa L, Wells RG, Lodish HF, Henis YI. 1998. Oligomeric structure of type I and type II transforming growth factor b receptors: Homodimers form in the ER and persist at the plasma membrane. J Cell Biol 140: 767-777.
67. Glinka Y, Prud’homme GJ. 2008. Neuropilin-1 is a receptor for latent and active TGFb-1and is involved in suppression by regulatory T cells. FASEB J 22: 664.4.
68. Glinka Y, Stoilova S, Mohammed N, Prud’homme GJ. 2011. Neuropilin-1 exerts co-receptor function for TGF-β-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-β. Carcinogenesis 32: 613-621.
69. Goto K, Kamiya Y, Imamura T, Miyazono K, Miyazawa K. 2007. Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors. J Biol Chem 282: 20603-20611.
70. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P. 2003. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFb/ALK5 signaling. Mol Cell 12: 817-828.
71. Gray PC, Shani G, Aung K, Kelber J, Vale W. 2006. Cripto binds transforming growth factor b (TGF-β) and inhibits TGF-β signaling. Mol Cell Biol 26: 9268-9278.
72. Griswold-Prenner I, Kamibayashi C, Maruoka EM, Mumby MC, Derynck R. 1998. Physical and functional interactions between type I transforming growth factor b receptors and Ba, a WD-40 repeat subunit of phosphatase 2A. Mol Cell Biol 18: 6595-6604.
73. Groppe J, Hinck CS, Samavarchi-Tehrani P, Zubieta C, Schuermann JP, Taylor AB, Schwarz PM, Wrana JL, Hinck AP. 2008. Cooperative assembly of TGF-β superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell 29: 157-168.
74. Grotewold L, Plum M, Dildrop R, Peters T, Ruther U. 2001. Bambi is coexpressed with BMP-4 during mouse embryogenesis. Mech Dev 100: 327-330.
75. Gudey SK, Sundar R, Mu Y, Wallenius A, Zang G, Bergh A, Heldin CH, Landstrom M. 2014. TRAF6 stimulates the tumor-promoting effects of TGFb type I receptor through polyubiquitination and activation of presenilin 1. Sci Signa l 7: ra2.
76. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. 2002. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-b receptors I and II. J Biol Chem 277: 29197-29209.
77. Guo M, Jiang ZF, Zhang XM, Lu DY, Ha AD, Sun JH, Du WZ, Wu ZC, Hu L, Khadarian K, et al. 2014. miR-656 inhibits glioma tumorigenesis through repression of BMPR1A. Carcinogenesis 35: 1698-1706.
78. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, et al. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312: 117-121.
79. Hart PJ, Deep S, Taylor AB, Shu Z, Hinck CS, Hinck AP. 2002. Crystal structure of the human TbR2 ectodomain-TGF-β3 complex. Nat Struct Biol 9: 203-208.
80. Hatsell SJ, Idone V, Wolken DMA, Huang L, Kim HJ, Wang LL, Wen XL, Nannuru KC, Jimenez J, Xie LQ, et al. 2015. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med 7: 303-137.
81. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone MAJ, Wrana JL, et al. 1997. The MAD-related protein Smad7 associates with the TGFb receptor and functions as an antagonist of TGFb signaling. Cell 89: 1165-1173.
82. Hayes S, Chawla A, Corvera S. 2002. TGF b receptor internalization into EEA1-enriched early endosomes: Role in signaling to Smad2. J Cell Biol 158: 1239-1249.
83. He XC, Zhang JW, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zeng X, He X, Wiedemann LM, et al. 2004. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-b-catenin signaling. Nat Genet 36: 1117-1121.
84. Heldin CH, Lu B, Evans R, Gutkind S. 2014. Signals and receptors. In Signal transduction principles, pathways and processes (ed. Cantley LC, Hunter T, Sever R, Thorner J), pp. 3-29. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
85. Henis YI, Moustakas A, Lin HY, Lodish HF. 1994. The types II and III transforming growth factor-b receptors form homo-oligomers. J Cell Biol 126: 139-154.
86. Herhaus L, Sapkota GP. 2014. The emerging roles of deubiquitylating enzymes (DUBs) in the TGFb and BMP pathways. Cell Signal 26: 2186-2192.
87. Herhaus L, Al-Salihi MA, Dingwell KS, Cummins TD, Wasmus L, Vogt J, Ewan R, Bruce D, Macartney T, Weidlich S, et al. 2014. USP15 targets ALK3/BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling. Open Biol 4: 140065.
88. Hocevar BA, Smine A, Xu XX, Howe PH. 2001. The adaptor molecule disabled-2 links the transforming growth factor β receptors to the Smad pathway. EMBO J 20: 2789-2801.
89. Horbelt D, Guo G, Robinson PN, Knaus P. 2010. Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity. J Cell Sci 123: 4340-4350.
90. Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, Traverso G, Vogelstein B. 2001. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 28: 184-187.
91. Howe JR, Sayed MG, Ahmed AF, Ringold J, Larsen-Haidle J, Merg A, Mitros FA, Vaccaro CA, Petersen GM, Giardiello FM, et al. 2004. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet 41: 484-491.
92. Huang T, David L, Mendoza V, Yang Y, Villarreal M, De K, Sun L, Fang X, Lopez-Casillas F, Wrana JL, et al. 2011. TGF-β signalling is mediated by two autonomously functioning TbRI:TbRII pairs. EMBO J 30: 1263-1276.
93. Huang SD, Holzel M, Knijnenburg T, Schlicker A, Roepman P, McDermott U, Garnett M, Grernrum W, Sun C, Prahallad A, et al. 2012. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell 151: 937-950.
94. Huminiecki L, Goldovsky L, Freilich S, Moustakas A, Ouzounis CA, Heldin CH. 2009. Emergence, development and diversification of the TGF-β signalling pathway within the animal kingdom. BMC Evol Biol 9: 28.
95. Huse M, Chen YG, Massagué J, Kuriyan J. 1999. Crystal structure of the cytoplasmic domain of the type I TGF b receptor in complex with FKBP12. Cell 96: 425-436.
96. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massagué J. 2001. The TGF b receptor activation process: An inhibitor-to substrate-binding switch. Mol Cell 8: 671-682.
97. Inui M, Manfrin A, Mamidi A, Martello G, Morsut L, Soligo S, Enzo E, Moro S, Polo S, Dupont S, et al. 2011. USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat Cell Biol 13: 1368-1375.
98. Ishida W, Hamamoto T, Kusanagi K, Yagi K, Kawabata M, Takehara K, Sampath TK, Kato M, Miyazono K. 2000. Smad6 is a Smad1/5-induced Smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter. J Biol Chem 275: 6075-6079.
99. Jadrich JL, O’Connor MB, Coucouvanis E. 2006. The TGF b activated kinase TAK1 regulates vascular development in vivo. Development 133: 1529-1541.
100. Jin W, Kim BC, Tognon C, Lee HJ, Patel S, Lannon CL, Maris JM, Triche TJ, Sorensen PH, Kim SJ. 2005. The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-β signaling by inactivating the TGF-β type II receptor. Proc Natl Acad Sci 102: 16239-16244.
101. Jin Q, Ding W, Mulder KM. 2007a. Requirement for the dynein light chain km23-1 in a Smad2-dependent transforming growth factor-b signaling pathway. J Biol Chem 282: 19122-19132.
102. Jin W, Yun C, Kim HS, Kim SJ. 2007b. TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling. Cancer Res 67: 9869-9877.
103. Jin W, Yun C, Kwak MK, Kim TA, Kim SJ. 2007c. TrkC binds to the type II TGF-β receptor to suppress TGF-β signaling. Oncogene 26: 7684-7691.
104. Jin QY, Ding W, Mulder KM. 2012. The TGFb receptor-interacting protein km23-1/DYNLRB1 plays an adaptor role in TGFb1 autoinduction via its association with Ras. J Biol Chem 287: 26453-26463.
105. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, et al. 1996. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13: 189-195.
106. Kamiya Y, Miyazono K, Miyazawa K. 2010. Smad7 inhibits transforming growth factor-b family type I receptors through two distinct modes of interaction. J Biol Chem 285: 30804-30813.
107. Kandoth C, McLellan MD, Vandin F, Ye K, Niu BF, Lu C, Xie MC, Zhang QY, McMichael JF, Wyczalkowski MA, et al. 2013. Mutational landscape and significance across 12 major cancer types. Nature 502: 333-339.
108. Kang JS, Saunier EF, Akhurst RJ, Derynck R. 2008. The type I TGF-β receptor is covalently modified and regulated by sumoylation. Nat Cell Biol 10: 654-664.
109. Kang H, Louie J, Weisman A, Sheu-Gruttadauria J, Davis-Dusenbery BN, Lagna G, Hata A. 2012. Inhibition of MicroRNA-302 (miR-302) by bone morphogenetic protein 4 (BMP4) facilitates the BMP signaling pathway. J Biol Chem 287: 38656-38664.
110. Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, Groppe J, Shore EM. 2008. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 22: 191-205.
111. Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, et al. 2009. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 30: 379-390.
112. Karbiener M, Neuhold C, Opriessnig P, Prokesch A, Bogner-Strauss JG, Scheideler M. 2011. MicroRNA-30c promotes human adipocyte differentiation and co-represses PAI-1 and ALK2. RNA Biol 8: 850-860.
113. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. 2000. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation. Mol Cell 6: 1365-1375.
114. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, Allgayer H, Guckel B, Fehm T, Schneeweiss A, et al. 2012. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kB and TGF-β signaling pathways. Oncogene 31: 4150-4163.
115. Kim SI, Kwak JH, Na HJ, Kim JK, Ding Y, Choi ME. 2009. Transforming growth factor-b (TGF-β1) activates TAK1 via TAB1-mediated autophosphorylation, independent of TGF-β receptor kinase activity in mesangial cells. J Biol Chem 284: 22285-22296.
116. Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, Blobe GC. 2008. Bone morphogenetic proteins signal through the transforming growth factor-b type III receptor. J Biol Chem 283: 7628-7637.
117. Kirsch T, Sebald W, Dreyer MK. 2000. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol 7: 492-496.
118. Knelson EH, Gaviglio AL, Tewari AK, Armstrong MB, Mythreye K, Blobe GC. 2013. Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma. J Clin Invest 123: 4786-4798.
119. Kotzsch A, Nickel J, Seher A, Heinecke K, van Geersdaele L, Herrmann T, Sebald W, Mueller TD. 2008. Structure analysis of bone morphogenetic protein-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome. J Biol Chem 283: 5876-5887.
120. Kovacs RJ, Maldonado G, Azaro A, Fernandez MS, Romero FL, Sepulveda-Sanchez JM, Corretti M, Carducci M, Dolan M, Gueorguieva I, et al. 2015. Cardiac safety of TGF-β receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study. Cardiovasc Toxicol 15: 309-323.
121. Kowanetz M, Valcourt U, Bergström R, Heldin CH, Moustakas A. 2004. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor β and bone morphogenetic protein. Mol Cell Biol 24: 4241-4254.
122. Kowanetz M, Lönn P, Vanlandewijck M, Kowanetz K, Heldin CH, Moustakas A. 2008. TGFβ induces SIK to negatively regulate type I receptor kinase signaling. J Cell Biol 182: 655-662.
123. Kwak JH, Kim SI, Kim JK, Choi ME. 2008. BAT3 interacts with transforming growth factor-b (TGF-β) receptors and enhances TGF-β1-induced type I collagen expression in mesangial cells. J Biol Chem 283: 19816-19825.
124. Lawler S, Feng XH, Chen RH, Maruoka EM, Turck CW, Griswold-Prenner I, Derynck R. 1997. The type II transforming growth factor-b receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J Biol Chem 272: 14850-14859.
125. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, ten Dijke P. 2004. Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J 23: 4018-4028.
126. Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, Smith SM, Derynck R. 2007. TGF-β activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 26: 3957-3967.
127. Lee NY, Ray B, How T, Blobe GC. 2008. Endoglin promotes transforming growth factor b-mediated Smad 1/5/8 signaling and inhibits endothelial cell migration through its association with GIPC. J Biol Chem 283: 32527-32533.
128. Lee NY, Kirkbride KC, Sheu RD, Blobe GC. 2009. The transforming growth factor-b type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Mol Biol Cell 20: 4362-4370.
129. Lee-Hoeflich ST, Causing CG, Podkowa M, Zhao X, Wrana JL, Attisano L. 2004. Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis. EMBO J 23: 4792-4801.
130. LeMaire SA, Pannu H, Tran-Fadulu V, Carter SA, Coselli JS, Milewicz DM. 2007. Severe aortic and arterial aneurysms associated with a TGFBR2 mutation. Nat Clin Pract Cardiovasc Med 4: 167-171.
131. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W. 2000. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 404: 411-414.
132. Li L, Liu YX, Guo Y, Liu B, Zhao YR, Li P, Song FJ, Zheng H, Yu JP, Song TQ, et al. 2015. Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatology 61: 574-584.
133. Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, Nayar R, Wu XF, Schuh AC. 2002. Cell surface antigen CD109 is a novel member of the a2 macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99: 1683-1691.
134. Lin HK, Bergmann S, Pandolfi PP. 2004. Cytoplasmic PML function in TGF-β signalling. Nature 431: 205-211.
135. Liu XJ, Yue JB, Frey RS, Zhu QC, Mulder KM. 1998. Transforming growth factor b signaling through smad1 in human breast cancer cells. Cancer Res 58: 4752-4757.
136. Liu C, Xu P, Lamouille S, Xu J, Derynck R. 2009a. TACE-mediated ectodomain shedding of the type I TGF-β receptor downregulates TGF-β signaling. Mol Cell 35: 26-36.
137. Liu IM, Schilling SH, Knouse KA, Choy L, Derynck R, Wang XF. 2009b. TGFb-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFb switch. EMBO J 28: 88-98.
138. Liu JQ, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, Ancukiewicz M, Boucher Y, Jain RK, Xu L. 2012. TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci 109: 16618-16623.
139. Liu WJ, Li XL, Zhao YS, Meng XM, Wan C, Yang BX, Lan HY, Lin HY, Xia Y. 2013. Dragon (repulsive guidance molecule RGMb) inhibits E-cadherin expression and induces apoptosis in renal tubular epithelial cells. J Biol Chem 288: 31528-31539.
140. Liu S, Nheu T, Luwor R, Nicholson SE, Zhu HJ. 2015. SPSB1, a novel negative regulator of the transforming growth factor-b signaling pathway targeting the type II receptor. J Biol Chem 290: 17894-17908.
141. Lo RS, Chen YG, Shi Y, Pavletich NP, Massagué J. 1998. The L3 loop: A structural motif determining specific interactions between SMAD proteins and TGF-β receptors. EMBO J 17: 996-1005.
142. Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, et al. 2005. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 37: 275-281.
143. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, De Backer JF, Oswald GL, Symoens S, Manouvrier S, et al. 2006. Aneurysm syndromes caused by mutations in the TGF-β receptor. N Engl J Med 355: 788-798.
144. Lönn P, Vanlandewijck M, Raja E, Kowanetz M, Watanabe Y, Kowanetz K, Vasilaki E, Heldin CH, Moustakas A. 2012. Transcriptional induction of salt-inducible kinase 1 by transforming growth factor β leads to negative regulation receptor system. Cell 67: 785-795.
145. López-Casillas F, Wrana JL, Massagué J. 1993. Betaglycan presents ligand to the TGF-β signaling receptor. Cell 73: 1435-1444.
146. López-Casillas F, Payne HM, Andres JL, Massagué J. 1994. Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: Mapping of ligand binding and GAG attachment sites. J Cell Biol 124: 557-568.
147. Loveland KL, Bakker M, Meehan T, Christy E, von Schonfeldt V, Drummond A, de Kretser D. 2003. Expression of Bambi is widespread in juvenile and adult rat tissues and is regulated in male germ cells. Endocrinology 144: 4180-4186.
148. Luo K. 2004. Ski and SnoN: Negative regulators of TGF-β signaling. Curr Opin Genet Dev 14: 65-70.
149. Luo KX, Lodish HF. 1997. Positive and negative regulation of type II TGFb receptor signal transduction by autophos-phorylation on multiple serine residues. EMBO J 16: 1970-1981.
150. Luo T, Cui SJ, Bian CJ, Yu XC. 2014. Crosstalk between TGF-β/Smad3 and BMP/BMPR2 signaling pathways via miR-17-92 cluster in carotid artery restenosis. Mol Cell Biochem 389: 169-176.
151. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA III, Newman J, Williams D, Galie N, et al. 2001. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68: 92-102.
152. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. 2004. Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 23: 552-563.
153. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298: 1912-1934.
154. Mao SS, Li HQ, Sun Q, Zen K, Zhang CY, Li L. 2014. miR-17 regulates the proliferation and differentiation of the neural precursor cells during mouse corticogenesis. FEBS J 281: 1144-1158.
155. Martello G, Zacchigna L, Inui M, Montagner M, Adorno M, Mamidi A, Morsut L, Soligo S, Tran U, Dupont S, et al. 2007. MicroRNA control of Nodal signalling. Nature 449: 183-188.
156. Massagué J. 2012. TGFb signalling in context. Nat Rev Mol Cell Biol 13: 616-630.
157. Massagué J, Seoane J, Wotton D. 2005. Smad transcription factors. Genes Dev 19: 2783-2810.
158. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, Murrell J, et al. 1994. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8: 345-351.
159. Mendoza V, Vilchis-Landeros MM, Mendoza-Hernandez G, Huang T, Villarreal MM, Hinck AP, Lopez-Casillas F, Montiel JL. 2009. Betaglycan has two independent domains required for high affinity TGF-β binding: Proteolytic cleavage separates the domains and inactivates the neutralizing activity of the soluble receptor. Biochemistry 48: 11755-11765.
160. Meng Q, Lux A, Holloschi A, Li J, Hughes JM, Foerg T, McCarthy JE, Heagerty AM, Kioschis P, Hafner M, et al. 2006. Identification of Tctex2b, a novel dynein light chain family member that interacts with different transforming growth factor-b receptors. J Biol Chem 281: 37069-37080.
161. Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, De Antonellis P, von Stedingk K, Ghesquiere B, Schulte S, Dews M, et al. 2010. The miR-17-92 MicroRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell 40: 762-773.
162. Meyer AE, Gatza CE, How T, Starr M, Nixon AB, Blobe GC. 2014. Role of TGF-β receptor III localization in polarity and breast cancer progression. Mol Biol Cell 25: 2291-2304.
163. Mitchell H, Choudhury A, Pagano RE, Leof EB. 2004. Ligand-dependent and -independent transforming growth factor-b receptor recycling regulated by clathrin-mediated endocytosis and Rab11. Mol Biol Cell 15: 4166-4178.
164. Miyazono K, Kamiya Y, Morikawa M. 2010. Bone morphogenetic protein receptors and signal transduction. J Biochem 147: 35-51.
165. Mizuguchi T, Collod-Beroud G, Akiyama T, Abifadel M, Harada N, Morisaki T, Allard D, Varret M, Claustres M, Morisaki H, et al. 2004. Heterozygous TGFBR2 mutations in Marfan syndrome. Nat Genet 36: 855-860.
166. Mohammad KS, Javelaud D, Fournier PGJ, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A, Guise TA. 2011. TGF-β-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 71: 175-184.
167. Moustakas A, Heldin CH. 2005. Non-Smad TGF-β signals. J Cell Sci 118: 3573-3584.
168. Moustakas A, Heldin CH. 2009. The regulation of TGFβ signal transduction. Development 136: 3699-3714.
169. Moustakas A, Lin HY, Henis YI, Plamondon J, O’Connor-McCourt MD, Lodish HF. 1993. The transforming growth factor b receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand. J Biol Chem 268: 22215-22218.
170. Mu Y, Sundar R, Thakur N, Ekman M, Gudey SK, Yakymovych M, Hermansson A, Dimitriou H, Bengoechea-Alonso MT, Ericsson J, et al. 2011. TRAF6 ubiquitinates TGFβ type I receptor to promote its cleavage and nuclear translocation in cancer. Nat Commun 2: 330.
171. Mura M, Cappato S, Giacopelli F, Ravazzolo R, Bocciardi R. 2012. The role of the 30 UTR region in the regulation of the ACVR1/Alk-2 gene expression. PLoS ONE 7: e50958.
172. Murphy SJ, Dore JJ, Edens M, Coffey RJ, Barnard JA, Mitchell H, Wilkes M, Leof EB. 2004. Differential trafficking of transforming growth factor-b receptors and ligand in polarized epithelial cells. Mol Biol Cell 15: 2853-2862.
173. Murphy SJ, Shapira KE, Henis YI, Leof EB. 2007. A unique element in the cytoplasmic tail of the type II transforming growth factor-b receptor controls basolateral delivery. Mol Biol Cell 18: 3788-3799.
174. Mythreye K, Blobe GC. 2009. The type III TGF-β receptor regulates epithelial and cancer cell migration through β-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci 106: 8221-8226.
175. Nagaoka T, Karasawa H, Castro NP, Rangel MC, Salomon DS, Bianco C. 2012. An evolving web of signaling networks regulated by Cripto-1. Growth Factors 30: 13-21.
176. Nakao A, Afrakhte M, Morén A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, et al. 1997. Identification of Smad7, a TGFb-inducible antagonist of TGF-β signalling. Nature 389: 631-635.
177. Neil JR, Tian M, Schiemann WP. 2009. X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-β-mediated nuclear factor-kB activation during breast cancer progression. J Biol Chem 284: 21209-21217.
178. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. 2003. Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33: 407-411.
179. Nieminen TT, Abdel-Rahman WM, Ristimaki A, Lappalainen M, Lahermo P, Mecklin JP, Jarvinen HJ, Peltomaki P. 2011. BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 141: E23-E26.
180. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI, Knaus P. 2002. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 277: 5330-5338.
181. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Dellus H, Massagué J, Niehrs C. 1999. Silencing of TGF-β signalling by the pseudoreceptor BAMBI. Nature 401: 480-485.
182. Oved S, Mosesson Y, Zwang Y, Santonico E, Shtiegman K, Marmor MD, Kochupurakkal BS, Katz M, Lavi S, Cesareni G, et al. 2006. Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J Biol Chem 281: 21640-21651.
183. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. 2005. Regulation of the polarity protein Par6 by TGFb receptors controls epithelial cell plasticity. Science 307: 1603-1609.
184. Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E, Giampietro PF, Zaleski C, Estrera AL, Safi HJ, et al. 2005. Mutations in transforming growth factor-b receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 112: 513-520.
185. Parikh VN, Jin RC, Rabello S, Gulbahce N, White K, Hale A, Cottrill KA, Shaik RS, Waxman AB, Zhang YY, et al. 2012. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension results of a network bioinformatics approach. Circulation 125: 1520-1531.
186. Park SO, Lee YJ, Seki T, Hong KH, Fliess N, Jiang Z, Park A, Wu X, Kaartinen V, Roman BL, et al. 2008. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 111: 633-642.
187. Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, Nabi IR, Wrana JL, Dennis JW. 2004. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306: 120-124.
188. Penheiter SG, Mitchell H, Garamszegi N, Edens M, Dore JJ Jr, Leof EB. 2002. Internalization-dependent and -independent requirements for transforming growth factor b receptor signaling via the Smad pathway. Mol Cell Biol 22: 4750-4759.
189. Penheiter SG, Singh RD, Repellin CE, Wilkes MC, Edens M, Howe PH, Pagano RE, Leof EB. 2010. Type II transforming growth factor-b receptor recycling is dependent upon the clathrin adaptor protein Dab2. Mol Biol Cell 21: 4009-4019.
190. Peterson RS, Andhare RA, Rousche KT, Knudson W, Wang W, Grossfield JB, Thomas RO, Hollingsworth RE, Knudson CB. 2004. CD44 modulates Smad1 activation in the BMP-7 signaling pathway. J Cell Biol 166: 1081-1091.
191. Petritsch C, Beug H, Balmain A, Oft M. 2000. TGF-β inhibits p70 S6 kinase via protein phosphatase 2A to induce G1 arrest. Genes Dev 14: 3093-3101.
192. Porsch H, Mehic M, Olofsson B, Heldin P, Heldin CH. 2014. Platelet-derived growth factor b-receptor, transforming growth factor b type I receptor, and CD44 protein modulate each other’s signaling and stability. J Biol Chem 289: 19747-19757.
193. Qiu T, Wu X, Zhang F, Clemens TL, Wan M, Cao X. 2010. TGF-β type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat Cell Biol 12: 224-234.
194. Radaev S, Zou ZC, Huang T, Lafer EM, Hinck AP, Sun PD. 2010. Ternary complex of transforming growth factor-β 1 reveals isoform-specific ligand recognition and receptor recruitment in the superfamily. J Biol Chem 285: 14806-14814.
195. Ray BN, Lee NY, How T, Blobe GC. 2010. ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. Carcinogenesis 31: 435-441.
196. Razani B, Zhang XL, Bitzer M, von Gersdorff G, Böttinger EP, Lisanti MP. 2001. Caveolin-1 regulates transforming growth factor (TGF)-b/SMAD signaling through an interaction with the TGF-β type I receptor. J Biol Chem 276: 6727-6738.
197. Rechtman MM, Nakaryakov A, Shapira KE, Ehrlich M, Henis YI. 2009. Different domains regulate homomeric and heteromeric complex formation among type I and type II transforming growth factor-b receptors. J Biol Chem 284: 7843-7852.
198. Rodon J, Carducci M, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly A, et al. 2015a. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs 33: 357-370.
199. Rodon J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly AL, et al. 2015b. First-in-human dose study of the novel transforming growth factor-b receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res 21: 553-560.
200. Rudini N, Felici A, Giampietro C, Lampugnani M, Corada M, Swirsding K, Garre M, Liebner S, Letarte M, ten Dijke P, et al. 2008. VE-cadherin is a critical endothelial regulator of TGF-β signalling. EMBO J 27: 993-1004.
201. Saetrom P, Biesinger J, Li SM, Smith D, Thomas LF, Majzoub K, Rivas GE, Alluin J, Rossi JJ, Krontiris TG, et al. 2009. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res 69: 7459-7465.
202. Samad TA, Rebbapragada A, Bell E, Zhang Y, Sidis Y, Jeong SJ, Campagna JA, Perusini S, Fabrizio DA, Schneyer AL, et al. 2005. DRAGON, a bone morphogenetic protein coreceptor. J Biol Chem 280: 14122-14129.
203. Sammar M, Stricker S, Schwabe GC, Sieber C, Hartung A, Hanke M, Oishi I, Pohl J, Minami Y, Sebald W, et al. 2004. Modulation of GDF5/BRI-b signalling through interaction with the tyrosine kinase receptor Ror2. Genes Cells 9: 1227-1238.
204. Satow R, Kurisaki A, Chan TC, Hamazaki TS, Asashima M. 2006. Dullard promotes degradation and dephosphorylation of BMP receptors and is required for neural induction. Dev Cell 11: 763-774.
205. Saunier EF, Akhurst RJ. 2006. TGF b inhibition for cancer therapy. Curr Cancer Drug Targets 6: 565-578.
206. Scaffidi AK, Petrovic N, Moodley YP, Fogel-Petrovic M, Kroeger KM, Seeber RM, Eidne KA, Thompson PJ, Knight DA. 2004. avb3 Integrin interacts with the transforming growth factor b (TGFβ) type II receptor to potentiate the proliferative effects of TGFβ1 in living human lung fibroblasts. J Biol Chem 279: 37726-37733.
207. Scherner O, Meurer SK, Tihaa L, Gressner AM, Weiskirchen R. 2007. Endoglin differentially modulates antagonistic transforming growth factor-b1 and BMP-7 signaling. J Biol Chem 282: 13934-13943.
208. Schiemann WP, Rotzer D, Pfeifer WM, Levi E, Rai KR, Knaus P, Kadin ME. 2004. Transforming growth factor-β (TGF-β)-resistant B cells from chronic lymphocytic leukemia patients contain recurrent mutations in the signal sequence of the type I TGF-β receptor. Cancer Detect Prev 28: 57-64.
209. Schwappacher R, Weiske J, Heining E, Ezerski V, Marom B, Henis YI, Huber O, Knaus P. 2009. Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity. EMBO J 28: 1537-1550.
210. Sebald W, Nickel J, Zhang JL, Mueller TD. 2004. Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction. Biol Chem 385: 697-710.
211. Sekiya T, Oda T, Matsuura K, Akiyama T. 2004. Transcriptional regulation of the TGF-β pseudoreceptor BAMBI by TGF-β signaling. Biochem Biophys Res Commun 320: 680-684.
212. Senanayake U, Das S, Vesely P, Alzoughbi W, Frohlich LF, Chowdhury P, Leuschner I, Hoefler G, Guertl B. 2012. miR-192, miR-194, miR-215, miR-200c and miR-141 are downregulated and their common target ACVR2B is strongly expressed in renal childhood neoplasms. Carcinogenesis 33: 1014-1021.
213. Seong HA, Jung H, Choi HS, Kim KT, Ha H. 2005. Regulation of transforming growth factor-b signaling and PDK1 kinase activity by physical interaction between PDK1 and serine-threonine kinase receptor-associated protein. J Biol Chem 280: 42897-42908.
214. Seong HA, Jung H, Ha H. 2007. NM23-H1 tumor suppressor physically interacts with serine-threonine kinase receptor-associated protein, a transforming growth factor-β (TGF-β) receptor-interacting protein, and negatively regulates TGF-β signaling. J Biol Chem 282: 12075-12096.
215. Shi W, Sun C, He B, Xiong W, Shi X, Yao D, Cao X. 2004. GADD34-PP1c recruited by Smad7 dephosphorylates TGFb type I receptor. J Cell Biol 164: 291-300.
216. Shi W, Chang C, Nie S, Xie S, Wan M, Cao X. 2007. Endofin acts as a Smad anchor for receptor activation in BMP signaling. J Cell Sci 120: 1216-1224.
217. Shibuya H, Iwata H, Masuyama N, Gotoh Y, Yamaguchi K, Irie K, Matsumoto K, Nishida E, Ueno N. 1998. Role of TAK1 and TAB1 in BMP signaling in early Xenopus development. EMBO J 17: 1019-1028.
218. Shim JH, Greenblatt MB, Xie M, Schneider MD, Zou W, Zhai B, Gygi S, Glimcher LH. 2009. TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J 28: 2028-2041.
219. Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, et al. 2006. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38: 525-527.
220. Singh KK, Rommel K, Mishra A, Karck M, Haverich A, Schmidtke J, Arslan-Kirchner M. 2006. TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome. Hum Mutat 27: 770-777.
221. Siragam V, Rutnam ZJ, Yang WN, Fang L, Luo LL, Yang XL, Li MH, Deng ZQ, Qian J, Peng C, et al. 2012. MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget 3: 1370-1385.
222. Sorensen LK, Brooke BS, Li DY, Urness LD. 2003. Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFb coreceptor. Dev Biol 261: 235-250.
223. Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N, Zhang S, Heldin CH, Landström M. 2008. The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 10: 1199-1207.
224. Souchelnytskyi S, ten Dijke P, Miyazono K, Heldin CH. 1996. Phosphorylation of Ser165 in TGF-β type I receptor modulates TGF-β1-induced cellular responses. EMBO J 15: 6231-6240.
225. Souchelnytskyi S, Tamaki K, Engström U, Wernstedt C, ten Dijke P, Heldin CH. 1997. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-β signaling. J Biol Chem 272: 28107-28115.
226. Spiekerkoetter E, Tian XF, Cai J, Hopper RK, Sudheendra D, Li CYG, El-Bizri N, Sawada H, Haghighat R, Chan R, et al. 2013. FK506 activates BMPR2 rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 123: 3600-3613.
227. Stenvers KL, Tursky ML, Harder KW, Kountouri N, Amatayakul-Chantler S, Grail D, Small C, Weinberg RA, Sizeland AM, Zhu HJ. 2003. Heart and liver defects and reduced transforming growth factor b2 sensitivity in–transforming growth factor b type III receptor-deficient embryos. Mol Cell Biol 23: 4371-4385.
228. Su Y, Zhang L, Gao X, Meng F, Wen J, Zhou H, Meng A, Chen YG. 2007. The evolutionally conserved activity of Dapper2 in antagonizing TGF-β signaling. FASEB J 21: 682-690.
229. Subramanyam D, Lamouille S, Judson RL, Liu JY, Bucay N, Derynck R, Blelloch R. 2011. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 29: 443-448.
230. Sun Q, Mao SS, Li HQ, Zen K, Zhang CY, Li L. 2013. Role of miR-17 family in the negative feedback loop of bone morphogenetic protein signaling in neuron. PLoS ONE 8: e83067.
231. Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM, et al. 2007. A novel small-molecule inhibitor of transforming growth factor b type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67: 2351-2359.
232. Tam BYY, Germain L, Philip A. 1998. TGF-β receptor expression on human keratinocytes: A 150 kDa GPI-anchored TGF-β1 binding protein forms a heteromeric complex with type I and type II receptors. J Cell Biochem 70: 573-586.
233. Tang Q, Staub CM, Gao G, Jin Q, Wang Z, Ding W, Aurigemma RE, Mulder KM. 2002. A novel transforming growth factor-b receptor-interacting protein that is also a light chain of the motor protein dynein. Mol Biol Cell 13: 4484-4496.
234. Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C, Castel D, Grasso CS, Vinci M, Carvalho D, et al. 2014. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46: 457-461.
235. Tazat K, Hector-Greene M, Blobe GC, Henis YI. 2015. TbRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling. Mol Biol Cell 26: 3535-3545.
236. ten Dijke P, Arthur HM. 2007. Extracellular control of TGFβ signalling in vascular development and disease. Nat Rev Mol Cell Biol 8: 857-869.
237. Thomson J, Machado R, Pauciulo M, Morgan N, Yacoub M, Corris P, McNeil K, Loyd J, Nichols W, Trembath R. 2001. Familial and sporadic primary pulmonary hypertension is caused by BMPR2 gene mutations resulting in haploinsufficiency of the bone morphogenetic protein type II receptor. J Heart Lung Transplant 20: 149.
238. Tsang M, Kim R, de Caestecker MP, Kudoh T, Roberts AB, Dawid IB. 2000. Zebrafish nma is involved in TGFβ family signaling. Genesis 28: 47-57.
239. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. 1998. SARA, a FYVE domain protein that recruits Smad2 to the TGFb receptor. Cell 95: 779-791.
240. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, et al. 2004. SD-208, a novel transforming growth factor b receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64: 7954-7961.
241. Valdimarsdóttir G, Goumans MJ, Itoh F, Itoh S, Heldin CH, ten Dijke P. 2006. Smad7 and protein phosphatase 1a are critical determinants in the duration of TGFb/ALK1 signaling in endothelial cells. BMC Cell Biol 7: 16.
242. van Dinther M, Visser N, de Gorter DJJ, Doorn J, Goumans MJ, de Boer J, ten Dijke P. 2010. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 25: 1208-1215.
243. van Meeteren LA, Thorikay M, Bergqvist S, Pardali E, Gallo Stampino C, Hu-Lowe D, Goumans MJ, Ten Dijke P. 2012. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem 287: 18551-18561.
244. Velasco S, Alvarez-Munoz P, Pericacho M, Dijke PT, Bernabeu C, Lopez-Novoa JM, Rodriguez-Barbero A. 2008. L-and S-endoglin differentially modulate TGFb1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci 121: 913-919.
245. Wakefield LM, Hill CS. 2013. Beyond TGFb: Roles of other TGFb superfamily members in cancer. Nat Rev Cancer 13: 328-341.
246. Wang T, Li B-Y, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Manganaro T, Donahoe PK. 1996. The immunophilin FKBP12 functions as a common inhibitor of the TGFb family type I receptors. Cell 86: 435-444.
247. Wang Q, Huang Z, Xue H, Jin C, Ju XL, Han JD, Chen Y-G. 2008. MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4. Blood 111: 588-595.
248. Wang B, Jha JC, Hagiwara S, McClelland AD, Jandeleit-Dahm K, Thomas MC, Cooper ME, Kantharidis P. 2014. Transforming growth factor-b 1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int 85: 352-361.
249. Weis-Garcia F, Massagué J. 1996. Complementation between kinase-defective and activation-defective TGF-β receptors reveals a novel form of receptor cooperativity essential for signaling. EMBO J 15: 276-289.
250. Wells RG, Gilboa L, Sun Y, Liu XD, Henis YI, Lodish HF. 1999. Transforming growth factor-b induces formation of a dithiothreitol-resistant type I/type II receptor complex in live cells. J Biol Chem 274: 5716-5722.
251. Wiater E, Harrison CA, Lewis KA, Gray PC, Vale WW. 2006. Identification of distinct inhibin and transforming growth factor β-binding sites on betaglycan: Functional separation of betaglycan co-receptor actions. J Biol Chem 281: 17011-17022.
252. Wong WK, Knowles JA, Morse JH. 2005. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: Implication for a role in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 33: 438-446.
253. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. 1994. Mechanism of activation of the TGF-β receptor. Nature 370: 341-347.
254. Wrighton KH, Lin X, Feng X-H. 2008. Critical regulation of TGFb signaling by Hsp90. Proc Natl Acad Sci 105: 9244-9249.
255. Wrighton KH, Lin X, Feng XH. 2009a. Phospho-control of TGF-β superfamily signaling. Cell Res 19: 8-20.
256. Wrighton KH, Lin X, Yu PB, Feng XH. 2009b. Transforming growth factor b can stimulate Smad1 phosphorylation independently of bone morphogenic protein receptors. J Biol Chem 284: 9755-9763.
257. Wu LY, Derynck R. 2009. Essential role of TGF-β signaling in glucose-induced cell hypertrophy. Dev Cell 17: 35-48.
258. Wu S, Lin Y, Xu D, Chen J, Shu M, Zhou Y, Zhu W, Su X, Zhou Y, Qiu P, et al. 2012. MiR-135a functions as a selective killer of malignant glioma. Oncogene 31: 3866-3874.
259. Xi Q, He W, Zhang XH, Le HV, Massague J. 2008. Genomewide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor b transcriptional program. J Biol Chem 283: 1146-1155.
260. Xia Y, Yu PB, Sidis Y, Beppu H, Bloch KD, Schneyer AL, Lin HY. 2007. Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4. J Biol Chem 282: 18129-18140.
261. Xu J, Wang AHJ, Oses-Prieto J, Makhijani K, Katsuno Y, Pei M, Yan LL, Zheng YG, Burlingame A, Bruckner K, et al. 2013. Arginine methylation initiates BMP-induced Smad signaling. Mol Cell 51: 5-19.
262. Yakymovych I, Yakymovych M, Zang G, Mu Y, Bergh A, Landström M, Heldin CH. 2015. CIN85 modulates TGFb signaling by promoting the presentation of TGFb receptors on the cell surface. J Cell Biol 210: 319-332.
263. Yamashita H, ten Dijke P, Franzén P, Miyazono K, Heldin CH. 1994. Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-β. J Biol Chem 269: 20172-20178.
264. Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE. 2008. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-β. Mol Cell 31: 918-924.
265. Yan YT, Liu JJ, Luo Y, E C, Haltiwanger RS, Abate-Shen C, Shen MM. 2002. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway. Mol Cell Biol 22: 4439-4449.
266. Yan X, Lin Z, Chen F, Zhao X, Chen H, Ning Y, Chen YG. 2009. Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-b signaling. J Biol Chem 284: 30097-30104.
267. Yan X, Zhang J, Pan L, Wang P, Xue H, Zhang L, Gao X, Zhao X, Ning Y, Chen YG. 2011. TSC-22 promotes transforming growth factor b-mediated cardiac myofibroblast differentiation by antagonizing Smad7 activity. Mol Cell Biol 31: 3700-3709.
268. Yan GJ, Zhang LX, Fang T, Zhang Q, Wu SG, Jiang Y, Sun HX, Hu YL. 2012. MicroRNA-145 suppresses mouse granulosa cell proliferation by targeting activin receptor IB. FEBS Lett 586: 3263-3270.
269. Yang H, Fang F, Chang RM, Yang LY. 2013. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor b receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology 58: 205-217.
270. Yao DY, Ehrlich M, Henis YI, Leof EB. 2002. Transforming growth factor-b receptors interact with AP2 by direct binding to b2 subunit. Mol Biol Cell 13: 4001-4012.
271. Ye G, Fu GD, Cui SY, Zhao SF, Bernaudo S, Bai Y, Ding YF, Zhang YO, Yang BB, Peng C. 2011. MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: Implications for chemoresistance. J Cell Sci 124: 359-368.
272. Yi JY, Shin I, Arteaga CL. 2005. Type I transforming growth factor b receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem 280: 10870-10876.
273. Yin XQ, Murphy SJ, Wilkes MC, Ji Y, Leof EB. 2013. Retromer maintains basolateral distribution of the type II TGF-β receptor via the recycling endosome. Mol Biol Cell 24: 2285-2298.
274. Yingling JM, Blanchard KL, Sawyer JS. 2004. Development of TGF-β signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3: 1011-1022.
275. You HJ, Bruinsma MW, How T, Ostrander JH, Blobe GC. 2007. The type III TGF-β receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis 28: 2491-2500.
276. Yumoto K, Thomas PS, Lane J, Matsuzaki K, Inagaki M, Ninomiya-Tsuji J, Scott GJ, Ray MK, Ishii M, Maxson R, et al. 2013. TGF-β-activated kinase 1 (Tak1) mediates agonist-induced Smad activation and linker region phosphorylation in embryonic craniofacial neural crest-derived cells. J Biol Chem 288: 13467-13480.
277. Zeng Y, Qu XB, Li HL, Huang S, Wang SH, Xu QL, Lin RZ, Han Q, Li J, Zhao RC. 2012. MicroRNA-100 regulates osteogenic differentiation of human adipose-derived mesenchymal stem cells by targeting BMPR2. FEBS Lett 586: 2375-2381.
278. Zhang W, Jiang Y, Wang Q, Ma X, Xiao Z, Zuo W, Fang X, Chen YG. 2009a. Single-molecule imaging reveals transforming growth factor-b-induced type II receptor dimerization. Proc Natl Acad Sci 106: 15679-15683.
279. Zhang Y, Li X, Qi J, Wang J, Liu X, Zhang H, Lin SC, Meng A. 2009b. Rock2 controls TGFb signaling and inhibits mesoderm induction in zebrafish embryos. J Cell Sci 122: 2197-2207.
280. Zhang M, Kleber S, Rohrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U, et al. 2011. Blockade of TGF-β signaling by the TGFβ R-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 71: 7155-7167.
281. Zhang L, Zhou F, Drabsch Y, Gao R, Snaar-Jagalska BE, Mickanin C, Huang H, Sheppard KA, Porter JA, Lu CX, et al. 2012. USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nat Cell Biol 14: 717-726.
282. Zhang L, Zhou FF, de Vinuesa AG, de Kruijf EM, Mesker WE, Hui L, Drabsch Y, Li YH, Bauer A, Rousseau A, et al. 2013a. TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis. Mol Cell 51: 559-572.
283. Zhang Q, Sun HX, Jiang Y, Ding LJ, Wu SG, Fang T, Yan GJ, Hu YL. 2013b. MicroRNA-181a suppresses mouse granulosa cell proliferation by targeting activin receptor IIA. PLoS ONE 8: 59667.
284. Zhong ZJ, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, Jimenez X, Prewett M, Liebisch G, Persaud K, et al. 2010. Anti-transforming growth factor b receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res 16: 1191-1205.
285. Zhou J, Lee PL, Lee CI, Wei SY, Lim SH, Lin TE, Chien S, Chiu JJ. 2013. BMP receptor-integrin interaction mediates responses of vascular endothelial Smad1/5 and proliferation to disturbed flow. J Thromb Haemost 11: 741-755.
286. Zumbrennen-Bullough KB, Wu QF, Core AB, Canali S, Chen WJ, Theurl I, Meynard D, Babitt JL. 2014. Micro-RNA-130a is up-regulated in mouse liver by iron deficiency and targets the bone morphogenetic protein (BMP) receptor ALK2 to attenuate BMP signaling and hepcidin transcription. J Biol Chem 289: 23796-23808.
287. Zuo W, Huang F, Chiang YJ, Li M, Du J, Ding Y, Zhang T, Lee HW, Jeong LS, Chen YL, et al. 2013. c-Cbl-Mediated neddylation antagonizes ubiquitination and degradation of the TGF-β type II receptor. Mol Cell 49: 499-510.